Argent Biopharma Ltd. to Acquire AusCann Assets, Expanding Clinical Pipeline and European Presence

Reuters

Aug 19, 2025

Argent Biopharma Ltd. to Acquire AusCann Assets, Expanding Clinical Pipeline and European Presence

Argent Biopharma Ltd. has announced the signing of a binding term sheet to acquire key assets and intellectual property from AusCann Group Holdings Ltd. This acquisition includes the Neuvis® drug delivery platform, FDA-facing epilepsy pre-clinical data, and access to EU-GMP manufacturing along with German pharmaceutical distribution. This strategic move enhances Argent's clinical pipeline and European commercial infrastructure, aligning with plans for a dual listing on a U.S. stock exchange. The integration of these assets is set to transform Argent's clinical execution and commercial reach, bolstering its IP-driven revenue model. The transaction is expected to be completed in Q3 2025, with integration activities already in progress.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief on August 19, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2560113468"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560113468\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560113468?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-19 07:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560113468","market":"nz","top_or_hot":-1,"title":"Argent Biopharma Ltd. to Acquire AusCann Assets, Expanding Clinical Pipeline and European Presence","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Argent Biopharma Ltd. to Acquire AusCann Assets, Expanding Clinical Pipeline and European Presence\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Argent Biopharma Ltd. has announced the signing of a binding term sheet to acquire key assets and intellectual property from AusCann Group Holdings Ltd. This acquisition includes the Neuvis® drug delivery platform, FDA-facing epilepsy pre-clinical data, and access to EU-GMP manufacturing along with German pharmaceutical distribution. This strategic move enhances Argent's clinical pipeline and European commercial infrastructure, aligning with plans for a dual listing on a U.S. stock exchange. The integration of these assets is set to transform Argent's clinical execution and commercial reach, bolstering its IP-driven revenue model. The transaction is expected to be completed in Q3 2025, with integration activities already in progress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief on August 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Argent Biopharma Ltd. to Acquire AusCann Assets, Expanding Clinical Pipeline and European Presence</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArgent Biopharma Ltd. to Acquire AusCann Assets, Expanding Clinical Pipeline and European Presence\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-19 07:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Argent Biopharma Ltd. to Acquire AusCann Assets, Expanding Clinical Pipeline and European Presence\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Argent Biopharma Ltd. has announced the signing of a binding term sheet to acquire key assets and intellectual property from AusCann Group Holdings Ltd. This acquisition includes the Neuvis® drug delivery platform, FDA-facing epilepsy pre-clinical data, and access to EU-GMP manufacturing along with German pharmaceutical distribution. This strategic move enhances Argent's clinical pipeline and European commercial infrastructure, aligning with plans for a dual listing on a U.S. stock exchange. The integration of these assets is set to transform Argent's clinical execution and commercial reach, bolstering its IP-driven revenue model. The transaction is expected to be completed in Q3 2025, with integration activities already in progress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief on August 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL50dYp1:1","article_id":"2560113468","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560113468","pubTimestamp":1755560790,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Argent Biopharma Ltd. has announced the signing of a binding term sheet to acquire key assets and intellectual property from AusCann Group Holdings Ltd. This acquisition includes the Neuvis drug delivery platform, FDA-facing epilepsy pre-clinical data, and access to EU-GMP manufacturing along with German pharmaceutical distribution. This strategic move enhances Argent's clinical pipeline and European commercial infrastructure, aligning with plans for a dual listing on a U.S. stock exchange. The integration of these assets is set to transform Argent's clinical execution and commercial reach, bolstering its IP-driven revenue model. The transaction is expected to be completed in Q3 2025, with integration activities already in progress.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interprete","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","RGT.AU":"Argent BioPharma Limited"},"translate_title":"Argent Biopharma Ltd.将收购AusCann资产，扩大临床产品线和欧洲业务","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGT.AU":0.9},"content_text":"Argent Biopharma Ltd. to Acquire AusCann Assets, Expanding Clinical Pipeline and European Presence\n    \n\n        Argent Biopharma Ltd. has announced the signing of a binding term sheet to acquire key assets and intellectual property from AusCann Group Holdings Ltd. This acquisition includes the Neuvis® drug delivery platform, FDA-facing epilepsy pre-clinical data, and access to EU-GMP manufacturing along with German pharmaceutical distribution. This strategic move enhances Argent's clinical pipeline and European commercial infrastructure, aligning with plans for a dual listing on a U.S. stock exchange. The integration of these assets is set to transform Argent's clinical execution and commercial reach, bolstering its IP-driven revenue model. The transaction is expected to be completed in Q3 2025, with integration activities already in progress.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief on August 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}